PriceTargets.com logo

Corbus Pharmaceuticals - CRBP Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $59.13
  • Forecasted Upside: 658.99%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 1 Strong Buy Ratings
$7.79 As of 05/2/2025 05:00 PM ET
▲ +0.27 (3.59%)

This chart shows the closing price for CRBP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
MarApr$7.79Closing price on 05/02/25:
Get New Corbus Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRBP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRBP

Analyst Price Target is $59.13
▲ +658.99% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Corbus Pharmaceuticals in the last 3 months. The average price target is $59.13, with a high forecast of $88.00 and a low forecast of $35.00. The average price target represents a 658.99% upside from the last price of $7.79.

This chart shows the closing price for CRBP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
4/247/2410/241/255/255/26$3.44$25$46$67$88Closing price on 05/02/25: $7.79High$88.00Average$59.13Low$35.00




Current Consensus is Buy

The current consensus among 10 investment analysts is to buy stock in Corbus Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/7/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/5/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2025
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/2/2025
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2025

Latest Recommendations

  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/12/2025WedbushReiterated RatingOutperform$51.00
3/12/2025HC WainwrightReiterated RatingBuy ➝ Buy$75.00 ➝ $50.00
3/11/2025Jefferies Financial GroupLower TargetBuy ➝ Buy$70.00 ➝ $53.00
2/28/2025William BlairInitiated CoverageOutperform
2/18/2025HC WainwrightReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
2/10/2025HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $75.00
12/2/2024Piper SandlerInitiated CoverageOverweight$35.00
11/4/2024WedbushReiterated RatingOutperform$51.00
9/23/2024HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
9/20/2024B. RileyLower TargetBuy ➝ Buy$85.00 ➝ $40.00
9/20/2024MizuhoReiterated RatingOutperform ➝ Outperform$74.00 ➝ $74.00
9/20/2024WedbushLower TargetOutperform ➝ Outperform$85.00 ➝ $51.00
9/20/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$82.00 ➝ $82.00
8/28/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$82.00 ➝ $82.00
8/21/2024Lifesci CapitalUpgradeStrong-Buy
8/7/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$82.00 ➝ $82.00
8/7/2024OppenheimerBoost TargetOutperform ➝ Outperform$80.00 ➝ $88.00
8/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
7/30/2024WedbushInitiated CoverageOutperform$85.00
7/22/2024HC WainwrightReiterated RatingBuy$80.00
7/10/2024OppenheimerReiterated RatingOutperform ➝ Outperform$80.00 ➝ $80.00
6/26/2024B. RileyInitiated CoverageBuy$85.00
6/11/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$77.00 ➝ $82.00
6/3/2024OppenheimerBoost TargetOutperform ➝ Outperform$60.00 ➝ $80.00
5/13/2024Royal Bank of CanadaInitiated CoverageOutperform$77.00
5/8/2024OppenheimerBoost TargetOutperform ➝ Outperform$58.00 ➝ $60.00
3/13/2024OppenheimerReiterated RatingOutperform ➝ Outperform$51.00 ➝ $58.00
3/6/2024Jefferies Financial GroupUpgradeHold ➝ Buy$4.00 ➝ $46.00
1/29/2024OppenheimerBoost TargetOutperform ➝ Outperform$20.00 ➝ $51.00
8/9/2023OppenheimerReiterated RatingOutperform ➝ Outperform$22.00
5/10/2023OppenheimerUpgradeMarket Perform ➝ Outperform
3/8/2023HC WainwrightReiterated RatingBuy$3.00
2/14/2023HC WainwrightReiterated RatingBuy$3.00
11/23/2021Royal Bank of CanadaReiterated RatingHold$2.00
11/15/2021HC WainwrightReiterated RatingBuy$3.00
9/16/2021Roth CapitalReiterated RatingNeutral
3/16/2021OppenheimerReiterated RatingHold
10/8/2020HC WainwrightLower TargetBuy$6.00 ➝ $3.00
9/9/2020HC WainwrightLower TargetBuy$24.00 ➝ $6.00
9/8/2020OppenheimerDowngradeOutperform ➝ Market Perform
9/8/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$18.00 ➝ $2.50
9/8/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$22.00 ➝ $3.00
9/8/2020BTIG ResearchDowngradeBuy ➝ Neutral
9/8/2020Roth CapitalDowngradeBuy ➝ Neutral$40.00 ➝ $3.00
8/7/2020HC WainwrightReiterated RatingBuy$24.00
7/27/2020Jefferies Financial GroupBoost TargetBuy$17.00 ➝ $18.00
7/7/2020Roth CapitalInitiated CoverageBuy$40.00
6/29/2020OppenheimerReiterated RatingBuy$28.00
6/19/2020OppenheimerReiterated RatingBuy$28.00
6/16/2020BTIG ResearchInitiated CoverageBuy$22.00
6/4/2020NomuraBoost TargetBuy$12.00 ➝ $32.00
6/4/2020Nomura InstinetBoost TargetBuy$12.00 ➝ $32.00
5/13/2020NomuraReiterated RatingBuy$12.00
5/11/2020OppenheimerReiterated RatingBuy$28.00
(Data available from 5/2/2020 forward)

News Sentiment Rating

0.67 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 10 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2024
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2024
  • 4 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2024
  • 7 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/2/2025
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/1/2025
  • 3 very positive mentions
  • 16 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
3/3/2025
  • 6 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/2/2025
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/2/2025

Current Sentiment

  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Corbus Pharmaceuticals logo
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
Read More

Today's Range

Now: $7.79
Low: $7.40
High: $8.07

50 Day Range

MA: $6.38
Low: $4.92
High: $8.35

52 Week Range

Now: $7.79
Low: $4.64
High: $61.90

Volume

91,583 shs

Average Volume

363,317 shs

Market Capitalization

$95.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Corbus Pharmaceuticals?

The following Wall Street analysts have issued research reports on Corbus Pharmaceuticals in the last twelve months: B. Riley, HC Wainwright, Jefferies Financial Group Inc., Lifesci Capital, Mizuho, Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, StockNews.com, Wedbush, and William Blair.
View the latest analyst ratings for CRBP.

What is the current price target for Corbus Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Corbus Pharmaceuticals in the last year. Their average twelve-month price target is $59.13, suggesting a possible upside of 659.0%. Oppenheimer Holdings Inc. has the highest price target set, predicting CRBP will reach $88.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $35.00 for Corbus Pharmaceuticals in the next year.
View the latest price targets for CRBP.

What is the current consensus analyst rating for Corbus Pharmaceuticals?

Corbus Pharmaceuticals currently has 9 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRBP will outperform the market and that investors should add to their positions of Corbus Pharmaceuticals.
View the latest ratings for CRBP.

What other companies compete with Corbus Pharmaceuticals?

Other companies that are similar to Corbus Pharmaceuticals include ORIC Pharmaceuticals, COMPASS Pathways, Alpha Teknova, Heron Therapeutics and Arcturus Therapeutics. Learn More about companies similar to Corbus Pharmaceuticals.

How do I contact Corbus Pharmaceuticals' investor relations team?

Corbus Pharmaceuticals' physical mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company's listed phone number is (617) 963-0100 and its investor relations email address is ir@corbuspharma.com. The official website for Corbus Pharmaceuticals is www.corbuspharma.com. Learn More about contacing Corbus Pharmaceuticals investor relations.